Biotech - Spark Newswire

2 minute read

BioVie Announces Completion Of Patient Enrollment In Phase 3 Trial Assessing NE3107 In Alzheimer’s Disease

Today, 9:28 AM

BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced

BIVI

1 minute read

UpHealth Expects FY2023 Revenues Of $127M-$135M Vs. $177.85M Estimate

By Benzinga Newsdesk

Today, 9:28 AM

This represents growth of 5% to 12% over pro forma 2022 revenue of $121 million. For comparison purposes, both the 2023 estimated revenue and 2022 pro forma revenue include five months of

UPH

1 minute read

FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s

By Vandana Singh

Today, 9:28 AM

The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…

GSK

1 minute read

Valneva Announced Additional Data From Remaining Studies And An Update On Regulatory Submissions For Its Inactivated Covid-19 Vaccine, VLA2001.

By Benzinga Newsdesk

Today, 9:28 AM

As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with

VALN

2 minute read

Why Inovio (INO) Shares Are Moving After-Hours

By Henry Khederian

Today, 9:28 AM

After falling initially in after-hours trading on Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are back up following the company report of worse-than-expected fourth-quarter financial results and announced topline results from REVEAL2.

INO

1 minute read

FDA
News

INOVIO Says Phase 2 REVEAL2 Trial Evaluating VGX-3100 Did Not Meet Primary Endpoint

By Benzinga Newsdesk

Today, 9:28 AM

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the primary endpoint in

INO

2 minute read

Semler Announces Clinical Study Published Using QuantaFlo As An Aid For Diagnosis Of Heart Dysfunction In The Primary Care Setting

By Happy Mohamed

Today, 9:28 AM

Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers (HCPs), today announced the publication of a study in

SMLR

1 minute read

AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says

By Vandana Singh

Today, 9:28 AM

Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…

ABBV

1 minute read

JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility

By Vandana Singh

Today, 9:28 AM

Guggenheim initiated the coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a $161 price target. The analyst agrees with the…

JNJ

1 minute read

Analyst Sits On Fence While Initiating Calliditas Citing ‘Near-Term Opportunity But Longer-Term Questions’

By Vandana Singh

Today, 9:28 AM

Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ:CALT) with a Neutral rating and an $18 price target. The analyst is impressed with…

CALT